Specialist and experienced pricing and market access consultancy
We will develop and implement a successful launch strategy for your product.
We build payer focussed pricing and market access strategies to enable commercial success.
We provide engaging training solutions that ensures your organisation stays ahead of the ever-changing market access landscape.
Unifying our internal strengths and external partnerships helps solve your pricing and market access challenges to drive patient access of your pharmaceutical products.
Clearly and concisely communicate key scientific, economic and commercial messages to enable company employees to effectively communicate the product’s value.
Individual solutions to suit you
We adapt our working style to reflect your needs
We have a wealth of practical knowledge & experience within the pharma industry & HTA bodies
We react quickly and effectively to provide the best support possible
The World Evidence, Pricing, and Access (EPA) Congress stands as Europe’s premier event in mar…
Read moreSafety signals have sparked vital discussions on patient access to ATMPs, marking a pivotal moment i…
Read moreObjectives The objective of this study is to explore the role of economic benefit in the HTA decisio…
Read moreThe study explores the complexities of pricing and reimbursement for multi-indication products in th…
Read moreConsultation launched on EU draft Regulation for joint clinical assessments, seeking feedback to imp…
Read moreWe discuss the 2024 VPAG agreement, how it differs from the previous VPAS and whether this will impa…
Read moreWebinar: Discussions on the new Voluntary Scheme for Branded Medicines, Pricing, Access and Growth (…
Read moreANSM establishes a Temporary Scientific Committee to promote biosimilar substitution, enhancing pati…
Read moreNew website provides regular updates on NLF’s work, addresses challenges, and showcases collaboratio…
Read moreNew biosimilar switching regulations prioritise cost-effective options and discount agreements, imp…
Read more